TMPRSS2 and prostate carcinoma: Research of over 1300 people found that combining PCA3 and TMPRSS2‐ERG measures in urine successfully identified groups with markedly different risks of cancer, high‐grade cancer, and clinically significant cancer on biopsy, exceeding serum PSA and single TMPRSS2‐ERG for prostate cancer diagnosis, decreasing wasteful biopsy and overdiagnosis, and laying the groundwork for precision prostate cancer care.130